

***Fiscal Year 2014 Breast Cancer Research Program
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Era of Hope Scholar Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: <u>W81XWH-14-BCRP-EOHS</u></p>	<p>Must be an independent, non-mentored investigator within 6 years of his/her last training position (e.g., postdoctoral fellowship, medical residency, clinical fellowship) as of the application submission deadline.</p>	<ul style="list-style-type: none"> • Supports exceptionally talented, creative early-career scientists who have demonstrated that they are the “best and brightest” in their fields. • Principal Investigators (PIs) should articulate a vision that challenges current dogma and demonstrates an ability to look beyond tradition and convention. • PIs should exhibit strong potential for leadership in the breast cancer community. • PIs must include breast cancer advocates on their research team. 	<ul style="list-style-type: none"> • The maximum period of performance is 5 years. • The maximum allowable funding for the entire period of performance is \$2.5 million (M) in direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. 	<p>Pre-Application (Letter of Intent): August 1, 2014 5:00 p.m. Eastern time (ET)</p> <p>Confidential Letters of Recommendation Submission Deadline: August 15, 2014 5:00 ET</p> <p>Application: August 15, 2014 11:59 p.m. ET</p>
<p>Innovator Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: <u>W81XWH-14-BCRP-INNOV</u></p>	<p>Must be an Associate Professor or above (or equivalent).</p>	<ul style="list-style-type: none"> • Supports visionary individuals who have demonstrated creativity, innovative work, and leadership in any field. • Provides opportunity to pursue novel, visionary, high-risk ideas that will accelerate progress toward ending breast cancer. • PIs must include breast cancer advocates on their research team. • <i>Nomination is required; self-nominations are accepted; application submission is by invitation only.</i> 	<ul style="list-style-type: none"> • The maximum period of performance is 5 years. • The maximum allowable funding for the entire period of performance is \$5M in direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. 	<p>Pre-Application (Nomination): May 14, 2014 5:00 p.m. ET</p> <p>Confidential Letters of Recommendation Submission Deadline: August 15, 2014 5:00 ET</p> <p>Invited Application: August 15, 2014 11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Breakthrough Award Levels 1 and 2</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>W81XWH-14-BCRP-BREAKTHROUGH12</p>	<ul style="list-style-type: none"> • Investigators at all academic levels (or equivalent) are eligible. • Postdoctoral fellows are eligible and encouraged to apply; additional applications components are required. • Each PI may submit only one application as a single PI or Initiating PI. 	<ul style="list-style-type: none"> • Supports promising research that has the potential to lead to or make breakthroughs in breast cancer. • Potential impact of the research may be near-term or long-term, but it must be significant and go beyond an incremental advancement. • Partnering PI Option allows two PIs, termed Initiating and Partnering PIs, to collaborate on a single application. • It is the responsibility of the PI to select the funding level that is most appropriate for the research proposed. • Submission of a Letter of Intent is required prior to full application submission. • Consumer advocate involvement is encouraged, but not required. • Clinical trials are not allowed. 	<p>Applications may be submitted under one of the following funding levels:</p> <p>Funding Level 1:</p> <ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$350,000 in direct costs. • The maximum period of performance is 3 years. <p>Funding Level 2:</p> <ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$700,000 in direct costs. • The maximum period of performance is 3 years. <p>Both Funding Levels:</p> <ul style="list-style-type: none"> • Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. 	<p>Pre-Application (Letter of Intent): May 14, 2014 5:00 p.m. ET</p> <p>Application: May, 28 2014 11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Breakthrough Award Levels 3 and 4</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>W81XWH-14-BCRP-BREAKTHROUGH34</p>	<ul style="list-style-type: none"> • Independent investigators at all academic levels (or equivalent) are eligible. • Each PI may submit only one application as a single PI or Initiating PI. 	<ul style="list-style-type: none"> • Supports promising research that has the potential to lead to or make breakthroughs in breast cancer. • Potential impact of the research may be near-term or long-term, but it must be significant and go beyond an incremental advancement. • Partnering PI Option allows two PIs, termed Initiating and Partnering PIs, to collaborate on a single application. • It is the responsibility of the PI to select the funding level that is most appropriate for the research proposed. • Submission of a preproposal is required; <i>application submission is by invitation only.</i> • Clinical trials are allowed. • Applicants are required to include breast cancer advocates on their research team. 	<p>Applications may be submitted under one of the following funding levels:</p> <p>Funding Level 3:</p> <ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$2.5M in direct costs. • The maximum period of performance is 5 years. <p>Funding Level 4:</p> <ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$10M in direct costs. • The maximum period of performance is 5 years. <p>Both Funding Levels:</p> <ul style="list-style-type: none"> • Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. 	<p>Pre-Application (Preproposal): May 14, 2014 5:00 p.m. ET</p> <p>Invited Application: August 15, 2014 11:59 p.m. ET</p>